Menu Search
Equities

Organon & Co

OGN:NYQ

Organon & Co

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)15.31
  • Today's Change0.415 / 2.79%
  • Shares traded1.00m
  • 1 Year change+36.17%
  • Beta0.7170
Data delayed at least 15 minutes, as of Nov 22 2024 18:15 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy0
Outperform4
Hold4
Sell2
Strong Sell0

Share price forecast in USD

The 7 analysts offering 12 month price targets for Organon & Co have a median target of 24.00, with a high estimate of 29.00 and a low estimate of 17.00. The median estimate represents a 61.18% increase from the last price of 14.89.
High94.8%29.00
Med61.2%24.00
Low14.2%17.00

Dividends

In 2023, Organon & Co reported a dividend of 1.12 USD, equaling last years dividend. The 5 analysts covering the company expect dividends of 1.25 USD for the upcoming fiscal year, an increase of 11.25%.
Div growth (TTM)0.00%
More ▼

Earnings history & estimates in USD

On Oct 31, 2024, Organon & Co reported 3rd quarter 2024 earnings of 0.87 per share. This result was in line with the consensus of the 7 analysts following the company and was the same as last year's 3rd quarter results.
The next earnings announcement is expected on Feb 13, 2025.
Average growth rate+2.32%
Organon & Co reported annual 2023 earnings of 4.14 per share on Feb 15, 2024.
Average growth rate-20.39%
More ▼

Revenue history & estimates in USD

Organon & Co had 3rd quarter 2024 revenues of 1.58bn. This bettered the 1.56bn consensus of the 6 analysts covering the company. This was 2.86% above the prior year's 3rd quarter results.
Average growth rate+1.06%
Organon & Co had revenues for the full year 2023 of 6.26bn. This was 1.44% above the prior year's results.
Average growth rate-0.31%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.